Physician profile
Amanda Barrett
NPI 1346609583
$8,282.00
in general payments reported to CMS, 2019-2025
32 companies · $1,736 in 2025
The $1,736 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,348 · 2022: $1,930 · 2023: $1,888 · 2024: $1,381 · 2025: $1,736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,968 · Education: $36.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,968.38 |
| Education | $36.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,635.89 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,016.45 | 2021-2025 | Caplyta |
| Lundbeck LLC | $809.49 | 2021-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $667.82 | 2021-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $657.90 | 2021-2025 | Rexulti, Abilify Mycite |
| Sunovion Pharmaceuticals INC. | $457.62 | 2021-2022 | |
| Corium, LLC | $333.57 | 2021-2025 | Azstarys |
| Almatica Pharma LLC | $314.23 | 2023-2025 | Loreev Xr |
| Teva Pharmaceuticals USA, INC. | $301.17 | 2021-2025 | Uzedy, Austedo, Austedo Xr |
| Ironshore Pharmaceuticals INC. | $241.63 | 2022-2024 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $211.84 | 2022-2024 | Invega Sustenna, Spravato, Invega |
| Alkermes, INC. | $190.54 | 2021-2025 | Aristada, Lybalvi |
| Neos Therapeutics, LP | $153.13 | 2021-2024 | Adzenys Xr-Odt |
| Axsome Therapeutics, INC. | $148.60 | 2022-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $140.48 | 2022-2025 | Fanapt, Hetlioz |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $118.93 | 2021-2022 | |
| Livanova USA, INC. | $113.74 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Noven Therapeutics, LLC | $104.04 | 2022-2025 | Xelstrym, Secuado |
| Neurocrine Biosciences, INC. | $89.05 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $86.44 | 2025 | Jornay Pm |
| Abbott Laboratories | $84.10 | 2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| E.R. Squibb & Sons, L.L.C. | $67.47 | 2025 | Cobenfy |
| Eisai INC. | $61.93 | 2021-2022 | |
| Bausch Health US, LLC | $57.18 | 2023-2025 | Aplenzin |
| Jazz Pharmaceuticals INC. | $52.66 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $32.88 | 2022 | |
| Sage Therapeutics, LLC | $26.58 | 2021 | |
| Owp Pharmaceuticals, INC. | $25.06 | 2021 | |
| Tempus Ai, INC | $25.00 | 2025 | Tempus Pixel |
| Biogen, INC. | $24.97 | 2024 | |
| Idorsia Pharmaceuticals US INC | $17.24 | 2023 | Quviviq |
| Indivior INC. | $14.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Barrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.